PepGen focuses on the development of technology underpinning the peptide-mediated delivery of nucleic acid drugs and was spun out from the University of Oxford in 2018. PepGen’s technology platform was developed through a decade-long scientific collaboration between co-founders Professor Matthew Wood (Oxford) and Dr Michael Gait (MRC Laboratory of Molecular Biology).
The company received initial seed funding from Oxford Sciences Innovation (OSI) to focus on commercialisation of the technology platform for neuromuscular disease indications.
The full story is available on the PepGen website